Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.
暂无分享，去创建一个
S. Gettinger | S. Ou | M. Ahn | D. Camidge | Dong-Wan Kim | Geoffrey Liu | M. Tiseo | Sang-We Kim | A. Delmonte | R. Huber | W. Reichmann | Y. Summers | J. Molina | M. Hochmair | K. Reckamp | A. Bearz | H. West | D. Kerstein | Santiago Viteri Ramírez